Cardiopulmonary disease - information, support and reception
1 – 10 of 111
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2025
-
Mark
Localization, Proteolytic Processing, and Binding Partners of Versican Isoforms in Vascular Lesions of Pulmonary Arterial Hypertension
2025) In The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society(
- Contribution to journal › Article
- 2024
-
Mark
The impact of cardiovascular and lung comorbidities in patients with pulmonary arterial hypertension : A systematic review and meta-analysis
(
- Contribution to journal › Scientific review
-
Mark
Change in health-related quality of life at early follow-up in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
(
- Contribution to journal › Article
-
Mark
Treatment for Rheumatoid Arthritis Associated With Alterations in the Gastrointestinal Microbiota
(
- Contribution to journal › Article
-
Mark
Left ventricular dysfunction in pulmonary arterial hypertension is attributed to underfilling rather than intrinsic myocardial disease : a CMR 2D phase contrast study
(
- Contribution to journal › Article
-
Mark
Treatment with mycophenolate mofetil is associated with improved nailfold vasculature in systemic sclerosis
(
- Contribution to journal › Article
-
Mark
Right ventricular stroke work index from echocardiography in patients with pulmonary arterial hypertension-the role in short-term follow-up assessment
(
- Contribution to journal › Article
-
Mark
Performance of the EULAR Systemic sclerosis Impact of Disease (ScleroID) questionnaire as a patient-reported outcome measure for patients with diffuse systemic sclerosis
(
- Contribution to journal › Article
-
Mark
Right ventricular dyssynchrony predicts outcome in pulmonary arterial hypertension when assessed in multiple cardiac magnetic resonance views
(
- Contribution to journal › Article
-
Mark
The Effect of Everolimus Versus Calcineurin Inhibitors on Quality of Life 10–12 Years After Heart Transplantation : The Results of a Randomized Controlled Trial (SCHEDULE Trial)
(
- Contribution to journal › Article